Key result
Torsemide offers an effective alternative to furosemide for cardiogenic pulmonary edema due to greater bioavailability.
Why the study?
Does torsemide improve the management of cardiogenic pulmonary edema compared to furosemide?
Does torsemide improve the management of cardiogenic pulmonary edema compared to furosemide?
Torsemide's pharmacological features, including greater bioavailability and absorption, make it a potentially better alternative to furosemide for managing cardiogenic pulmonary edema.
Answers are grounded in this paper and cite their sources.
May support torsemide in cardiogenic pulmonary edema; leaves open confirmation of superiority in randomized trials.
Pulmonary edema, either cardiogenic or noncardiogenic, is caused by fluid accumulation in the alveolar spaces. Cardiogenic pulmonary edema (CPE), one of the causes of congestive heart failure (CHF), is treated with loop diuretics. Torsemide and furosemide were found to be useful in the treatment of CHF-associated pulmonary edema due to their ability to lower pulmonary capillary pressure and left ventricular end-diastolic pressure, respectively. Pharmacological features of torsemide, such as greater bioavailability, higher absorption rate, and efficacy, make it a better alternative for treating pulmonary edema than the regularly used loop diuretic, furosemide. Torsemide administered intravenously was found to be both efficacious and well tolerated in CPE. However, more research is needed to determine its usefulness in non-CPE.
No takes yet. Share an insight, caveat, or question.
Vora et al. (2024) conducted a review in Pulmonary edema. Torsemide vs. Furosemide was evaluated. Torsemide is an efficacious and well-tolerated alternative to furosemide for treating cardiogenic pulmonary edema due to its greater bioavailability and higher absorption rate.
Synapse has enriched 10 related papers. Consider them for comparative context: